An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and ...

A drug candidate, previously successful at treating severe fatty liver disease, reduces atherosclerosis—a primary driver of ...

Not everyone is sold on the benefits of early ezetimibe use, especially given the modest effect seen in IMPROVE-IT.

Lowering cholesterol triggers other health problems. Mostly false. Prior to the introduction of statins four decades ago, ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

Pharmacy benefits manager CVS Health has warned that the new PCSK9 inhibitor class of cholesterol-lowering drugs poses an unprecedented challenge to the US healthcare system. In a blog post ...

Other medications, like ezetimibe and PCSK9 inhibitors, can also help lower LDL by reducing cholesterol absorption or increasing its clearance from the blood,” he explains. However, it is ...

BMY and VERV are in the spotlight this week following the failure of a late-stage study and positive cholesterol study data, ...

Inhibitors of LDL synthesis, lomitapide and mipomersen, are new therapeutic options. PCSK9 inhibitors are being evaluated in HoFH and seem to be effective if there is residual receptor activity.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...